Epithelial-to-mesenchymal transition in cancer: complexity and opportunities

[1]  A. Ben-Ze'ev.  Faculty Opinions recommendation of Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  T. Voet,et al.  Identification of the tumour transition states occurring during EMT , 2018, Nature.

[3]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[4]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[5]  R. Weinberg,et al.  Upholding a role for EMT in pancreatic cancer metastasis , 2017, Nature.

[6]  Jill P. Mesirov,et al.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.

[7]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[8]  J. Thiery,et al.  New insights into the role of EMT in tumor immune escape , 2017, Molecular oncology.

[9]  C. Pilarsky,et al.  The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer , 2017, Nature Cell Biology.

[10]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[11]  R. Weinberg,et al.  Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. , 2017, Cancer research.

[12]  R. Weinberg,et al.  Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells , 2017, Proceedings of the National Academy of Sciences.

[13]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[14]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[15]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[16]  T. Tan,et al.  The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200 , 2017, Oncoimmunology.

[17]  L. Byers,et al.  A phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) , 2016 .

[18]  Paul Martin,et al.  Wound repair: a showcase for cell plasticity and migration. , 2016, Current opinion in cell biology.

[19]  Robert A. Weinberg,et al.  Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability , 2016, Science.

[20]  James E. Verdone,et al.  Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters , 2016, Proceedings of the National Academy of Sciences.

[21]  M. Miyazaki,et al.  Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization , 2016, Genes & development.

[22]  G. Getz,et al.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[23]  Erik Sahai,et al.  Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization , 2015, Cell reports.

[24]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[25]  R. Weinberg,et al.  Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. , 2015, Trends in cell biology.

[26]  Chih-Yang Wang,et al.  Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells , 2015, Nature.

[27]  Jennifer M. Carr,et al.  Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity , 2015, Nature Cell Biology.

[28]  Michael B. Stadler,et al.  PIK3CAH1047R induces multipotency and multi-lineage mammary tumours , 2015, Nature.

[29]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[30]  R. Weinberg,et al.  Distinct EMT programs control normal mammary stem cells and tumour-initiating cells , 2015, Nature.

[31]  Yunyun Zhou,et al.  An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. , 2015, The Journal of clinical investigation.

[32]  Joshua M. Korn,et al.  Studying clonal dynamics in response to cancer therapy using high-complexity barcoding , 2015, Nature Medicine.

[33]  Andreas W. Schreiber,et al.  The RNA Binding Protein Quaking Regulates Formation of circRNAs , 2015, Cell.

[34]  Zhiqing Liang,et al.  CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition , 2015, Oncotarget.

[35]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[36]  S. Carr,et al.  A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages , 2014, Nature Cell Biology.

[37]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[38]  R. Weinberg,et al.  Tackling the cancer stem cells — what challenges do they pose? , 2014, Nature Reviews Drug Discovery.

[39]  K. Tsang,et al.  WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. , 2014, Cancer research.

[40]  Bogi Andersen,et al.  Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. , 2014, Developmental cell.

[41]  G. Christofori,et al.  The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion , 2014, Oncogene.

[42]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[43]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[44]  Jing Yang,et al.  Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.

[45]  C. Klein.  Selection and adaptation during metastatic cancer progression , 2013, Nature.

[46]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[47]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[48]  C. Sheridan.  First Axl inhibitor enters clinical trials , 2013, Nature Biotechnology.

[49]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[50]  G. Pan,et al.  Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT–MET mechanism for optimal reprogramming , 2013, Nature Cell Biology.

[51]  T. Tan,et al.  Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. , 2013, Cancer research.

[52]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[53]  Jing Yang,et al.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.

[54]  M. Nieto,et al.  Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. , 2012, Cancer cell.

[55]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[56]  Jean Paul Thiery,et al.  Epithelial-mesenchymal transitions: insights from development , 2012, Development.

[57]  Bruce G. Haffty,et al.  Elf5 inhibits epithelial mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2/Slug , 2012, Nature Cell Biology.

[58]  R. Weinberg,et al.  Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. , 2012, Cancer discovery.

[59]  P. Friedl,et al.  Classifying collective cancer cell invasion , 2012, Nature Cell Biology.

[60]  Ling Xia,et al.  Overexpression of Snail induces epithelial–mesenchymal transition and a cancer stem cell–like phenotype in human colorectal cancer cells , 2012, Cancer medicine.

[61]  B. Cieply,et al.  Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. , 2012, Cancer research.

[62]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[63]  Wenjun Guo,et al.  Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State , 2012, Cell.

[64]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[65]  A. Menssen,et al.  miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions , 2011, Cell cycle.

[66]  Nicholas C. Flytzanis,et al.  An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype , 2011, PLoS genetics.

[67]  A. Rangarajan,et al.  Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters , 2011, Cell Death and Disease.

[68]  Jun Qin,et al.  Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. , 2011, Cancer research.

[69]  Paul A. Wiggins,et al.  Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state , 2011, Proceedings of the National Academy of Sciences.

[70]  M. Hung,et al.  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[71]  Zhiwei Wang,et al.  Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells , 2010, PloS one.

[72]  B. Zhou,et al.  The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine‐specific demethylase 1 , 2010, The EMBO journal.

[73]  C. Iacobuzio-Donahue,et al.  Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. , 2010, Journal of the National Cancer Institute.

[74]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[75]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[76]  S. Morrison,et al.  Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.

[77]  D. Gilmour,et al.  EMT 2.0: shaping epithelia through collective migration. , 2009, Current opinion in genetics & development.

[78]  P. Friedl,et al.  Collective cell migration in morphogenesis, regeneration and cancer , 2009, Nature Reviews Molecular Cell Biology.

[79]  S. Krauss,et al.  Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma , 2009, Clinical & Experimental Metastasis.

[80]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[81]  Claude C. Warzecha,et al.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.

[82]  Yutaka Kawakami,et al.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. , 2009, Cancer cell.

[83]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[84]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[85]  K. Helin,et al.  Polycomb Complex 2 Is Required for E-cadherin Repression by the Snail1 Transcription Factor , 2008, Molecular and Cellular Biology.

[86]  M. Korpal,et al.  The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.

[87]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[88]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[89]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[90]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[91]  J. Aguirre-Ghiso,et al.  Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.

[92]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[93]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[94]  Thomas Kirchner,et al.  Migrating cancer stem cells — an integrated concept of malignant tumour progression , 2005, Nature Reviews Cancer.

[95]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[96]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[97]  M. Hung,et al.  Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition , 2004, Nature Cell Biology.

[98]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[99]  I. Fabregat,et al.  Snail blocks the cell cycle and confers resistance to cell death. , 2004, Genes & development.

[100]  H. Moses,et al.  Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro , 2004, Breast Cancer Research.

[101]  E. Ballestar,et al.  Snail Mediates E-Cadherin Repression by the Recruitment of the Sin3A/Histone Deacetylase 1 (HDAC1)/HDAC2 Complex , 2004, Molecular and Cellular Biology.

[102]  L. Nelles,et al.  Mice lacking ZFHX1B, the gene that codes for Smad-interacting protein-1, reveal a role for multiple neural crest cell defects in the etiology of Hirschsprung disease-mental retardation syndrome. , 2003, American journal of human genetics.

[103]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[104]  G. Naumov,et al.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. , 2002, Cancer research.

[105]  E. Carver,et al.  The Mouse Snail Gene Encodes a Key Regulator of the Epithelial-Mesenchymal Transition , 2001, Molecular and Cellular Biology.

[106]  J. Sundberg,et al.  The Slug gene is not essential for mesoderm or neural crest development in mice. , 1998, Developmental biology.

[107]  H. Kikutani,et al.  Impairment of  T Cell Development in δ EF1 Mutant Mice , 1997, The Journal of experimental medicine.

[108]  G. Berx,et al.  E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.

[109]  S. Barsky,et al.  Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. , 1996, The American journal of surgical pathology.

[110]  H. Allgayer,et al.  Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.

[111]  R. Behringer,et al.  twist is required in head mesenchyme for cranial neural tube morphogenesis. , 1995, Genes & development.

[112]  E. Hay,et al.  Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells , 1982, The Journal of cell biology.

[113]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[114]  Hollis G. Potter,et al.  Author Manuscript , 2013 .